Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
Fiche publication
Date publication
novembre 2017
Journal
Inflammatory bowel diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S
Lien Pubmed
Résumé
Several studies have reported a strong correlation between infliximab (IFX) trough levels (trough levels of infliximab [TLI]) and clinical remission (CR). We aimed to determine threshold values of TLI associated with the occurrence of CR, with or without normal inflammatory biomarkers, including serum C-reactive protein (CRP) and fecal calprotectin (fCal).
Mots clés
Adolescent, Adult, Biomarkers, analysis, C-Reactive Protein, analysis, Drug Monitoring, Feces, chemistry, Female, France, Gastrointestinal Agents, administration & dosage, Humans, Inflammatory Bowel Diseases, drug therapy, Infliximab, administration & dosage, Leukocyte L1 Antigen Complex, analysis, Logistic Models, Male, Middle Aged, Prospective Studies, ROC Curve, Remission Induction, Severity of Illness Index, Tertiary Care Centers, Young Adult
Référence
Inflamm. Bowel Dis.. 2017 11;23(11):2048-2053